FDA launches pilot to speed up early-stage clinical trials
The Food and Drug Administration on June 22 announced a pilot program intended to streamline the earliest phases of drug testing under the Investigational New Drug pathway. Officials said the changes could shave six to 12 months off development timelines, and the agency is seeking funding in the fiscal 2027 budget to make the expedited route permanent.
The effort was championed by former FDA Commissioner Marty Makary before his departure last month, and Health Secretary Robert F. Kennedy Jr. has argued the United States is losing ground to China in clinical research. The explicit aim is to keep more early-stage trials in the United States rather than ceding them to lower-cost competitors abroad.
The practical effect will depend on implementation details and on whether Congress funds the permanent pathway. Faster IND clearance lowers a real cost for developers, but the early phases it targets are primarily about safety screening, so the timeline savings accrue before the larger and more expensive efficacy trials that determine whether a drug reaches patients.